Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05767047 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05767047 · ClinicalTrials.gov record · last posted 2025-12-01

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

StatusRecruiting
PhasePhase 3
SponsorAmgen
Started2023-03-23
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.

Amendment record 15 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 15 times since 2023-03-08; most recent amendment 2025-11-26. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-03-29
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05767047
Lead Sponsor Amgen
Conditions Behçet's Disease, Juvenile Psoriatic Arthritis
Enrollment 48 participants
Start Date 2023-03-23
Primary Completion 2036-03-17 (estimated)
Study Completion 2036-03-17 (estimated)
Updated on ClinicalTrials.gov 2025-12-01